This study was designed to temporally relate plasma 6-ketoprostaglandin Fla, indomethacin con-
Since the introduction of indomethacin into neonatal practice for functional closure of the patent ductus arteriosus, this drug has become widely used.' Several double blind controlled trials have confirmed that it is effective in altering clinical signs of left to right shunt in low birthweight infants, [2] [3] [4] although the debate continues regarding optimal timing, route, and dosage.
Prostaglandins are considered an important factor in maintaining the patency of the preterm ductus. 6 Prostaglandin E is a more potent dilator of the isolated ductus preparation than prostacyclin,7 although the lamb ductus can be shown to generate only prostacyclin from the precursors.8 The stable metabolite of prostacyclin, 6-ketoprostaglandin Fla, is the major product of ductus homogenate.9
Prostacyclin may thus be of more importance than prostaglandin E in vivo.
Indomethacin is a potent but reversible inhibitor of cyclo-oxygenase, the enzyme that catalyses oxygenation of endoperoxides to their prostaglandin products."' Timing of onset of inhibition is not well defined. Reduction of urinary prostaglandin E metabolite in five healthy adults was 59-95% at 24 hours." Similar effects have been seen in neonates, with a resurgence of urinary prostaglandin E metabolite after six days corresponding with Assay was by radioimmunoassay of 100 Rl unextracted plasma. All assays were performed in duplicate in a medium of plasma free of prostaglandin. The tracer was iodinated 6-ketoprostaglandin Fl0, the antibody raised in rabbits (Seragen Ltd), and separation of bound from free was using a double antibody technique. The smallest quantity detectable was 25 pg/ml; intra-assay coefficient of variation was 6% and interassay coefficient of variation 16%. Cross sensitivity to prostaglandins A, D, E, F10, F2a, and 13, 14 dihydro 6-ketoprostaglandin Fl, was less than 1%.
Measurement of indomethacin. Estimation of indomethacin from blood collected into plain tubes simultaneously with the prostaglandin samples was performed using high pressure liquid chromatography.18 All reagents were analytical grade (British Drug Houses Ltd) and the chromatography was carried out using a 10 [tm radial-Pak C,8 reverse phase column (Waters Associates Ltd) and radial compression module (Waters Model RCM-100). The pump was Specta-Physics 8500A with variable wavelength detector and automatic integrator. The following chromatography conditions were used: mobile phase acetonitrile: water 45:55 vol:vol containing 0*5% acetic acid, flow rate 2 ml/min, wavelength 260 urm, detector range 0-02 absorbed unit full scale (AUFS), injection volume 100 RI, and temperature ambient. Plasma samples were extracted with ether, inclusion of 0-1 ml of 10 ,tg/ml-1 phenylbutazone solution (Geigy) was made into all samples as an internal control. The retention times for indomethacin and phenylbutazone were seven and 12 minutes, respectively.
The response of peak height was linear between 0-1 and 1 mg/ml. Calculation of unknowns was from the linear graph generated from extraction of samples prepared from drug free plasma to which a known mass of indomethacin was added. Recovery of indomethacin after extraction was 87%, and coefficient of variation for the assay had a mean value of 11% +5%. The lower limit of detection was 0-1 ,ug/ml-l. 6-Ketoprostaglandin Fl0 concentrations were rethacin prolonged bleeding duced by treatment with indomethacin with a treated infants were in the significant reduction compared with the pretreatrho had an indomethacin ment value and with the control group by six hours. Discussion estimations of prostaglandin performed the concentration was less than 50 pg/ml between the second and fifth day of life; two had high concentrations throughout the study (one died), there was one early death, and no late samples were obtained from a fourth infant. In 11 of 15, however, a significant rise was shown after the sixth day (p<0-001) ( Table 5 ).
P=0.037 S P=0.06
Treatment with indomethacin achieved a significant in vivo inhibition of prostacyclin synthesis in this group of low birthweight infants, and early treatment was associated with a prevention of ductal signs warranting intervention in the neonatal period. series20 21 was not confirmed, although the reduction of alveolar arterial oxygen gradient on the third day may have been due to a reduction of pulmonary oedema by early ductal closure. The effect of treatment with indomethacin on prostacyclin synthesis has been suggested to be dose related in adults,22 1 but the current neonatal dose is 10-fold less than that used in the original study23 and that administered to adult patients. Plasma concentrations after dosing showed a wide variation similar to previous results, again making precise recommendations for dosage difficult. 24 The timing of reduction of prostaglandin synthesis is in keeping with the clinical response and provides further indirect evidence that prostaglandins are a factor in the control of ductal tone. A fall in plasma prostaglandin E concentrations in two of three infants six hours after treatment with indomethacin has been shown. 25 This work does not support the concept that a threshold concentration of indomethacin is needed for either clinical effect or inhibition of prostaglandin synthesis.
The large number of infants suffering gastrointestinal haemorrhage included significantly more of the infants with high indomethacin concentrations.
Indomethacin exerts a potent and generalised effect on cyclo-oxygenase, that from platelets appearing particularly sensitive.26 A prolongation of bleeding time has been documented27 and is an undesirable effect resulting from inhibition of platelet thromboxane synthesis. Complications due to disturbances of haemostasis are common in the newborn, but in this group there was no excess incidence of intraventricular haemorrhage among treated infants. Other workers have observed that there has been no excess of intraventricular haemorrhage in infants receiving indomethacin for patent ductus and that indomethacin did not cause extension of intraventricular haemorrhage.28 The adverse effects on platelet function are possibly balanced in the ill infant by the concomitant removal of the vasodilating influence that prostacyclin exerts on the cerebral circulation.29 Loss of this effect on the renal microvasculature and reduction of renal blood flow almost certainly accounts for the rise of creatinine concentrations. 30 The observation that the duration of inhibition is of the order of four days is an important one and has clinical implications as the relapse rate is often high after treatment with indomethacin.3' Not all preterm infants will develop an appreciable left to right shunt, and we would not agree that 'prophylactic' treatment is completely safe.5 Perhaps the conclusion to be drawn from this study is that the way to use indomethacin in the preterm infant is to treat as soon as he develops signs with a small dose of intravenous indomethacin and to continue it daily for as long as a week. 
